

Date: January 30, 2024

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra East, Mumbai – 400051
takeover@nse.co.in

Subject: Disclosure under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011.

Dear Sir / Madam,

We, Oaklane Capital Management LLP, are a registered portfolio manager with the Securities and Exchange Board of India (**SEBI**). We are making this disclosure to you, in the prescribed format (*annexed to this letter*) in terms of the provisions of regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011.

Name of the Company: Hester Biosciences Limited

ISIN: INE782E01017

We trust this meets your requirements.

Sincerely,

For Oaklane Capital Management LLP



Ashwini Desai
Principal Officer



Encl: as above

Format for disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011			
Part-A- Details of the Acquisition			
Name of the Target Company (TC)	Hester Biosciences Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Oaklane Capital Management LLP (Portfolio Manager) and its clients. SEBI Registration Number INP000006624.		
Whether the acquirer belongs to Promoter/Promoter group	No.		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	1. BSE Limited 2. National Stock Exchange of India Limited 3. Metropolitan Stock Exchange of India Limited		
Details of the acquisition as follows	Number	% w.r.t. total share/ voting capital wherever applicable(*)	% w.r.t. total diluted share/ voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer alongwith PAC of:			
(a) Shares carrying voting rights	4,20,203	4.94%	4.94%
(b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	0%	0
(c) Voting rights (VR) otherwise than by equity shares	-	0%	0
(d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)	-	0%	0
(e) Total (a+b+c+d)	4,20,203	4.94%	4.94%
Details of acquisition			
(a) Shares carrying voting rights acquired	10,000	0.12%	0.12%
(b) VRs acquired otherwise than by equity shares	-	-	-
(c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	-	-	-
(d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
(e) Total (a+b+c+/-d)	10,000	0.12%	0.12%
After the acquisition, holding of acquirer along with PACs of:			
(a) Shares carrying voting rights	4,30,203	5.06%	5.06%
(b) VRs otherwise than by equity shares	-	-	-
(c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	-	-	-
(d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
(e) Total (a+b+c+d)	4,30,203	5.06%	5.06%

Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/encumbrance, etc.)	Shares are acquired through open market transaction(s) through stock exchange.
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	NA
Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	29th January 2024
Equity share capital / total voting capital of the TC before the said acquisition	85,06,865
Equity share capital/ total voting capital of the TC after the said acquisition	85,06,865
Total diluted share/voting capital of the TC after the said acquisition	85,06,865